Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph not_applicable

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

N/ANon-phased studies

2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Other(1)

Detailed Status

Recruiting1

unknown1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

recruiting133%

unknown133%

completed133%

Recent Activity

1 active trials

Showing 3 of 3

recruiting

Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children

NCT05054361

completednot_applicable

Role of ARMA in Selective Subset of Refractory GERD Patients.

NCT05899491

unknownnot_applicable

The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients

NCT02149914

Clinical Trials (3)

Showing 3 of 3 trials

NCT05054361

Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children

Recruiting

NCT05899491Not Applicable

Role of ARMA in Selective Subset of Refractory GERD Patients.

Completed

NCT02149914Not Applicable

The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients

Unknown

All 3 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 3